Abstract 1479P
Background
Refractory cancer pain (RCP) affects 10-20% of cancer patients, exhibiting limited response to standard opioids (OPI). Ketamine (KET), an anesthetic medication, has gained recent attention for its potential in managing RCP. This study aims to describe the consumption of rescue OPI before and after initiating KET, the rate of patients meeting a controlled pain criteria, and its safety profile.
Methods
A prospective observational study was conducted in three academic hospitals. Over an 18-month period, we included all cancer patients who initiated KET therapy based on the criteria of their treating medical team. The frequency of OPI rescues was recorded on days five (D-5) and two (D-2), and on days two (D+2) and five (D+5) pre and post KET initiation, respectively. Controlled pain criteria were defined as a 72-hour interval with no more than 3 OPI rescues per day, absence of breakthrough pain, and no escalation in OPI dosage. All adverse effects (AEs) were recorded in accordance with the CTCAE 5.0 guidelines.
Results
Fifty-two patients were included, and their characteristics are described in the table. The most common initiation dose of KET was 0.5 mg/kg/day orally (71.2%). Median oral morphine milligram equivalent (MME) at initiation of KET was 120mg. Overall survival from the onset of KET therapy was 43 days. Median daily OPI rescue was 3.90 on D-5 and 4.62 on D-2, decreasing to 2.79 on D+2 and 2.77 on D+5 (p=
Conclusions
A significant decrease in rescue opioids usage was observed after initiating ketamine. Over 60% of the patients met the criteria for controlled pain, with a favorable safety profile. Further comparative studies are required to better understand the role of ketamine in cancer pain.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vall d'Hebron University Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10